ImmunoCellular Therapeutics Ltd (IMUC) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 2 from a previous price target of $3 . Maxim Group advised their investors in a research report released on Aug 23, 2016.
ImmunoCellular Therapeutics Ltd closed down -0.0019 points or -1.51% at $0.1236 with 19,17,113 shares getting traded on Friday. Post opening the session at $0.128, the shares hit an intraday low of $0.1236 and an intraday high of $0.1283 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Dec 2, 2015, Andrew Gengos (CEO) purchased 10,000 shares at $0.44 per share price. According to the SEC, on Feb 20, 2015, Anthony Gringeri (Senior VP Strategic Resources) purchased 30,000 shares at $0.60 per share price. On Feb 20, 2015, David Fractor (VP of Finance) purchased 16,667 shares at $0.60 per share price, according to the Form-4 filing with the securities and exchange commission.
ImmunoCellular Therapeutics Ltd. is a clinical-stage biotechnology company. The Company’s cancer immunotherapies targets cancer stem cells (CSCs). Its product candidates include ICT-107 which completed phase II testing and also a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. ICT-107 the Company’s lead product candidate is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM) a type of brain cancer. In addition to ICT-107 the Company develops other therapeutic DC vaccines including ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-121 specifically targets CD133 a CSC marker that is overexpressed in a variety of solid tumors including ovarian pancreatic and breast cancers. Its product candidates also include stem cell therapies for cancer which is in pre-clinical-stage.